Document Detail


Comparison between metoprolol orally osmotic once daily and metoprolol two or three times daily in suppressing exercise-induced and daily myocardial ischemia.
MedLine Citation:
PMID:  8970407     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Metoprolol is a widely used anti-ischemic drug with a relatively short half-life. To improve patient' compliance and to provide 24-hour coverage, its once daily ORally OSmotic (OROS) formulation was developed. In this multicenter double-blind study, the anti-ischemic effects of metoprolol OROS given once daily at doses of 190 and 285 mg were compared to the regular metoprolol formulation of 100 mg 2 or 3 times daily. Sixty-five patients with stable coronary artery disease, positive exercise tests, and ischemic episodes during daily activity as recorded by ambulatory electrocardiographic monitoring (AEM) were included. In the OROS group, 23 patients completed all 3 treatment periods. In these patients, the number of myocardial ischemic episodes decreased from 239 on placebo to 128 during the 190 mg/day dose (p < 0.0001) and to 86 during the 285 mg/day treatment period (p < 0.0001). In the metoprolol group, there were 204 episodes at baseline and 142 and 140 during the 100 mg 2 or 3 times daily treatment periods (p < 0.0001 for both). During exercise testing, time to 1-mm ST depression increased significantly in the OROS group from 6.3 minutes at baseline to 7.1 and 9.6 minutes during 190- and 285-mg treatment periods. In the metoprolol group, it increased from 5.8 to 7.2 and 8.2 minutes, respectively. Both formulations of metoprolol were well tolerated. The OROS formulation was highly effective in suppressing daily and exercise-induced ischemia and exerted its effect throughout the 24-hour period.
Authors:
D Tzivoni; A Medina; D David; Y Barzilai; A Gavish; D Shatboon; A Keren; P Brunel
Related Documents :
3364807 - Prevention of vasospastic angina by alcohol ingestion: report of 2 cases.
9825197 - Modulation of ventricular rate in permanent atrial fibrillation: randomized, crossover ...
9829327 - Determinants of a positive exercise test in patients admitted with acute non-infarct ch...
6814227 - Comparative effects of abrupt withdrawal of propranolol and verapamil in angina pectoris.
1279567 - Initial clinical experience with a single pass vddr pacing system.
11168917 - Clenbuterol administration does not enhance the efficacy of furosemide in attenuating t...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The American journal of cardiology     Volume:  78     ISSN:  0002-9149     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  1996 Dec 
Date Detail:
Created Date:  1997-01-15     Completed Date:  1997-01-15     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1362-8     Citation Subset:  AIM; IM    
Affiliation:
Department of Cardiology, Shaare Zedek Medical Center, Tel Aviv, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Adrenergic beta-Antagonists / administration & dosage*,  therapeutic use
Adult
Aged
Dose-Response Relationship, Drug
Double-Blind Method
Drug Administration Schedule
Electrocardiography, Ambulatory
Exercise Test
Female
Humans
Male
Metoprolol / administration & dosage*,  therapeutic use
Middle Aged
Myocardial Ischemia / drug therapy*
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 37350-58-6/Metoprolol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Prognostic role of cardiovascular risk factors for men with cardiomegaly (the Reykjavik Study).
Next Document:  Results of intensive long-term treatment of familial hypercholesterolemia.